Moderna Swings to a Loss on Fewer Covid-19 Vaccine Sales

Core Insights - Moderna reported a loss in the third quarter and experienced a decline in sales as it seeks to diversify its product offerings in response to decreasing demand for its Covid-19 vaccine [1] Financial Performance - The company logged lower sales figures in the third quarter compared to previous periods, indicating a significant impact from the waning demand for its Covid-19 vaccine [1] Strategic Direction - Moderna is actively working to expand its product range to mitigate the effects of reduced demand for its primary vaccine offering [1]